Streptococcus Pneumoniae is a major cause of morbidity and mortality worldwide, with an estimated 1.6 million people dying of invasive pneumococcal disease (IPD) each year. IPD primarily comprises septicemia, pneumonia, and meningitis. However, S. Pneumoniae infections can also lead to other diseases such as bronchitis or pericarditis. IPD occurs most commonly among the very young (24 months) and the elderly (65 years); the elderly have the highest IPD mortality rates.
Market growth will be maintained by price rises, increased vaccination uptake in the elderly, and a stable infant population.
Prevnar 13 will continue to dominate US and EU markets, but pipeline vaccines could pose formidable threats from 2022.
V114 and GSK-3 will threaten the dominance of Prevnar 13 with potential for broader coverage, starting in 2022.
Key Topics Covered:
FORECAST: PNEUMOCOCCAL VACCINES (Published on 21 December 2018) Overview Forecast And Future Trends Market Definition And Methodology Primary Research Methodology Us Market Forecast Japan Market Forecast France Market Forecast Germany Market Forecast Italy Market Forecast Spain Market Forecast Uk Market Forecast Product Profile: Prevnar Product Profile (Late Stage): V114